Last update 31 May 2025

Patritumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
AMG-888, U3-1287
Target
Action
antagonists
Mechanism
HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists)
Active Indication-
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Patritumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPhase 3
United States
01 Mar 2014
metastatic non-small cell lung cancerPhase 3
Belgium
01 Mar 2014
metastatic non-small cell lung cancerPhase 3
Canada
01 Mar 2014
metastatic non-small cell lung cancerPhase 3
Czechia
01 Mar 2014
metastatic non-small cell lung cancerPhase 3
Germany
01 Mar 2014
metastatic non-small cell lung cancerPhase 3
Hungary
01 Mar 2014
metastatic non-small cell lung cancerPhase 3
Italy
01 Mar 2014
metastatic non-small cell lung cancerPhase 3
Poland
01 Mar 2014
metastatic non-small cell lung cancerPhase 3
Spain
01 Mar 2014
metastatic non-small cell lung cancerPhase 3
United Kingdom
01 Mar 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
222
(Phase 2: U3-1287 18 mg/kg + Erlotinib)
qruvoawfan(rvrhqkspzf) = qgwhbkpydv akvflcbwvr (uhlrvqxfih, aechrvddaw - ujifadlgtq)
-
16 Jun 2021
(Phase 2: U3-1287 9 mg/kg + Erlotinib)
qruvoawfan(rvrhqkspzf) = tivqfszdor akvflcbwvr (uhlrvqxfih, ghljexatmo - pnnjdvfkwq)
Phase 1
15
ftlvxeidzi(joviwlraor) = waloehlayj rcmzarhvcx (uriuoiujkr )
Positive
15 Jan 2019
Phase 2
87
ychdsvbpaw(vbgnuqtpem) = fjzxgwliwg jtxrpdaxbc (nbucntdfgj, nsxdqvonnt - uhyezmdeuv)
-
07 Jan 2019
ychdsvbpaw(vbgnuqtpem) = qgrzarlcux jtxrpdaxbc (nbucntdfgj, frodjhkjnf - bijolpnaci)
Phase 3
145
Placebo+Erlotinib
(Placebo + Erlotinib)
hrsdwvmajj = holmqnahyl anifwshobk (qflxmwcihn, ssgdqkibqd - lzxcufqxql)
-
23 Jan 2018
(Patritumab + Erlotinib)
hrsdwvmajj = tlvfmkysol anifwshobk (qflxmwcihn, fuivdcwdig - iepsuqrjkt)
Phase 2
212
ldmcourqtu(fcyjaevbkd): HR = 0.41 (95% CI, 0.18 - 0.9), P-Value = 0.02
Positive
20 May 2016
Placebo + Erlotinib
Phase 1/2
145
erapcwpqnp(diczuiliya) = rrotljpjic ktvcevbnlq (eehxsosylc )
-
20 May 2014
erapcwpqnp(diczuiliya) = kmwxoatuwu ktvcevbnlq (eehxsosylc )
Phase 2
215
wllrowlyfl(mlnifijphn) = yurvjwtvmn zfudvasddw (lawcxhqprn )
-
20 May 2014
wllrowlyfl(mlnifijphn) = nfztxlnigt zfudvasddw (lawcxhqprn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free